The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

NCT05078255 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Obesity

Interventions

DRUG: Semaglutide 1.34 MG/ML [Ozempic]
DRUG: Glucose-dependent insulinotropic polypeptide (GIP)
OTHER: Semaglutide 1.34 mg/ml placebo
OTHER: GIP placebo

Sponsor

Asger Lund, MD